Escitalopram

Generic Name
Escitalopram
Brand Names
Cipralex, Lexapro
Drug Type
Small Molecule
Chemical Formula
C20H21FN2O
CAS Number
128196-01-0
Unique Ingredient Identifier
4O4S742ANY
Background

Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication

Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions
Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)
Associated Therapies
-
Clinical Trials
Related News

Connectivity Affecting the Antidepressant REsponse Study

First Posted Date
2015-01-06
Last Posted Date
2021-09-21
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
95
Registration Number
NCT02332291
Locations
🇺🇸

Vanderbilt Psychiatric Hospital, Nashville, Tennessee, United States

Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

First Posted Date
2014-12-19
Last Posted Date
2016-03-14
Lead Sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
Target Recruit Count
3255526
Registration Number
NCT02320240
Locations
🇨🇦

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress

Phase 3
Completed
Conditions
ENT Cancer
Interventions
Drug: Escitalopram
Other: Placebo
First Posted Date
2014-09-22
Last Posted Date
2016-06-10
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
38
Registration Number
NCT02246244
Locations
🇫🇷

Gustave Roussy, Villejuif, Val de Marne, France

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

First Posted Date
2014-09-12
Last Posted Date
2014-09-12
Lead Sponsor
HolsboerMaschmeyer NeuroChemie GmbH
Target Recruit Count
80
Registration Number
NCT02237937
Locations
🇩🇪

Max Planck Institute of Psychiatry, Munich, Bavaria, Germany

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

First Posted Date
2014-07-16
Last Posted Date
2020-02-25
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
534
Registration Number
NCT02191397
Locations
🇨🇳

GSK Investigational Site, Wuhan, China

Study of Drug Combination on Pharmacokinetics in Healthy Volunteers

First Posted Date
2014-06-26
Last Posted Date
2015-02-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
41
Registration Number
NCT02175602

SSRI Study for Functional Dyspepsia (SS)

Phase 3
Completed
Conditions
Dyspepsia
Anxiety
Depression
Interventions
Other: Placebo
Drug: Escitalopram
First Posted Date
2014-06-03
Last Posted Date
2019-01-31
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
71
Registration Number
NCT02153567
Locations
🇭🇰

Prince of Wales Hospital, Hong Kong, Hong Kong

A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Escitalopram
First Posted Date
2014-04-25
Last Posted Date
2014-06-03
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
12
Registration Number
NCT02122939
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyounggi, Korea, Republic of

Developing New Clinical Management Strategies

Phase 4
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Escitalopram
First Posted Date
2014-03-10
Last Posted Date
2020-03-03
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
3
Registration Number
NCT02082392
Locations
🇺🇸

New York State Psychiatric Institute, New York, New York, United States

Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder

Phase 4
Conditions
Major Depressive Disorder
Interventions
Drug: escitalopram
First Posted Date
2013-11-28
Last Posted Date
2013-11-28
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
600
Registration Number
NCT01997580
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy